UPDATE 2-Johnson & Johnson edges past profit estimates, lifts outlook

UPDATE 2-Johnson & Johnson edges past profit estimates, lifts outlook


Johnson & Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. Shares were unchanged in premarket trading, with the company forecasting adjusted 2018 earnings per share in the range of $8.13 and $8.18, marginally up from a previous range of $8.07 to $8.17.



from Biotech News